Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma: A Phase 2 Trial

NCT04221516 is registered in ClinicalTrials.gov with Nanfang Hospital, Southern Medical University as lead sponsor.

NCT NCT04221516
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04221516 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma: A Phase 2 Trial
Lead sponsor
Nanfang Hospital, Southern Medical University
Phase
Phase 2
Overall status
Unknown status
Start date
January 1, 2020
Completion date
February 1, 2024
Enrollment
52 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nasopharyngeal carcinoma, oligometastasis, radiotherapy